Lantern Pharma CEO Panna Sharma Discusses Progress in AI-Driven Cancer Drug Development

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefiningoncology drug development through artificial intelligence. Its proprietary RADR® platform leveragesover 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patienttargeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC innever-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressiveB-cell lymphomas. The company also advances CNS oncology programs via its subsidiary StarlightTherapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with globalpartners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanningJohns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value throughprecision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit LTRNinfo.com to learn more.